

PRELIMINARY SCIENTIFIC PROGRAM

SCIENTIFIC PLANNING COMMITTEE

CO-CHAIRS

Pier Francesco Ferrucci – Istituto Europeo di Oncologia, Milano, IT

Christoph Hubert – Association for Cancer Immunotherapy, Mainz, DE

Arlene Sharpe - Harvard Medical School, Boston, MA, USA

Padmanee Sharma - MD Anderson Cancer Center, Houston, TX, USA

COMMITTEE

Mustafa Diken - Johannes Gutenberg University, Mainz, DE

Marina Garassino – University of Chicago, Chicago, IL, USA

Sue Kaeck – Salk Institute for Biological Studies, La Jolla, CA, USA

Nir Hacohen, Harvard Medical School, MA, USA

Paola Nisticò – Regina Elena National Cancer Institute, Roma, IT

Pamela Ohashi – University of Toronto, Toronto, CAN


Catherine Sautès-Fridman – Paris Descartes University, Paris, FR

Andrea Schietinger – Sloan Kettering Institute, New York, NY, USA

Özlem Türeci - BioNTech, Mainz, DE

Cassian Yee - MD Anderson Cancer Center, Houston TX, USA

Laurence Zitvogel – Gustave Roussy Institute, Villejuif, FR



Day 1 - Wednesday, September 20, 2023

2.00 – 2.40 pm

ENCI Lecture

Jim Allison – The University of Texas MD Anderson Cancer Centre (USA)
Immune Checkpoint Blockade in Cancer Therapy: historical perspective, new opportunities, and prospects for cures

2.45 – 4.30 pm

Session 1: *With a little help from my friends: innate immune cells and stromal cells in the tumor microenvironment*

Lisa Coussens - Knight Cancer Institute (USA)
Immune Vulnerabilities in Solid Tumors: Leukocyte Communication Networks Regulate Neoplastic Progression and Response to Therapy

Eric Vivier - Aix Marseille Université – INSERM - CNRS (France)
Harnessing Innate Immunity in Cancer Therapy

Shannon Turley - Genentech (USA)
Stromal Evolution in Cancer and Immunotherapy

2 Proffered talks

4.30 – 6.15 pm

Session 2: *Deranged T and B cells within the tumor microenvironment*
Andrea Schietinger - Sloan Kettering Institute (USA)


Yifat Merbl - Weizmann Institute (Israel)
Proteasomal profiling: From global views of degradation to novel mechanisms of anti-tumor immunity

Catherine Sautès-Fridman - University Paris Cité (France)
TLS and B cells in the immunotherapy response

2 Proffered talks

6.15 – 7.00 pm

William B. Coley Lecture
TBD



Day 2 - Thursday, September 21, 2023

8.30 – 10.15 am **Round table 1: Lung cancer at the forefront of cancer immunotherapy**
Marina Garassino – University of Chicago (USA)
Beyond PD-L1 in NSCLC

Sergio Quezada – UCL Cancer Institute – University (UK)
Regulatory T cell targeting at the interface of adaptive and innate function within tumours

Dieter Lambrecht – KU Leuven Center for Cancer Biology (Belgium)
Unraveling Tumor Immune responses during checkpoint immunotherapy using single-cell and spatial technologies

2 Proffered talks

General discussion

10.15 – 10.45 am **Break**

10.45 – 12.30 pm **Round table 2: Harnessing immunotherapy against breast cancer**
Marleen Kok – Netherlands Cancer Institute (The Netherlands)
Improving immunotherapy for breast cancer patients

Fatima Mechta-Grigoriou – Institut Curie (France)

Silvia Formenti – Weill Cornell Medicine (New York)


2 Proffered talks

General discussion

12.30 – 2.00 pm **Industry lunch meeting and poster session**

2.00 – 2.40 pm **Pezcoller Lecture**
Alberto Mantovani – Humanitas Research Institute (Italy)
Innate Immunity, Inflammation and Cancer: double edged swords

2.50 – 4.20 pm **Session 3: The earlier the better: neoadjuvant immunotherapy against cancer**
Padmanee Sharma – MD Anderson Cancer Center (USA)
Immune Checkpoint Therapy: Identifying Mechanisms of Response and Resistance



Christian Blank – The Netherlands Cancer Institute (The Netherlands)
Neoadjuvant Immunotherapy – next steps towards total personalization

Tina Cascone – MD Anderson Cancer Center (USA)
Advances in neoadjuvant and perioperative immunotherapy for lung cancer

1 Proffered talk

4.20 – 4.40 pm **Break**

4.40 – 6.35 pm **Session 4: Technologies, technologies, technologies: we need more**
Nir Hacohen – Harvard Medical School (USA)

Aaron Newman – Stanford Cancer Institute (USA)

Joakim Lundeberg - KTH Royal Institute of Technology (Sweden)
The cancer ecosystems captured by spatially resolved omics

1 Proffered talk

Day 3 – Friday, September 22, 2023

8.30 – 10.15 am **Round table 3: How to overcome resistance of poorly sensitive tumors to immunotherapy**
Andrea Alimonti – Università della Svizzera Italiana (Switzerland)

Vincenzo Bronte – Istituto Oncologico Veneto (Italy)

Ozlem Tureci – BioNTech (Germany)
mRNA-based immunotherapies

2 Proffered talks

General discussion


10.15 – 10.45 am **Break**

10.30 – 12.15 pm **Round table 4: Melanoma immunotherapy – learning from failure and success**
Tom Gajewski - The University of Chicago (USA)

Paolo Ascierto - Università degli Studi di Napoli Federico II (Italy)
Combination strategy to overcome resistance

Jeffrey Weber - NYU Langone New York (USA)

2 Proffered talks



General discussion

12.15 – 2.00 pm **Industry lunch meeting and poster session**

2.00 – 4.10 pm

Session 5: Metabolic barriers to cancer immunotherapy

Guido Kroemer - Université de Paris (France)

Improving the cancer-immune crosstalk by caloric restriction mimetics

Susan Kaech - Salk Institute for Biological Studies (USA)

Nutritional influence on T cell exhaustion

Antonio Sica - Humanitas University (Italy)

Metabolic dysregulation of myelopoiesis in cancer

Greg Delgoffe - University of Pittsburgh (USA)

Metabolic inputs and outputs of exhausted T cells in cancer

2 Proffered talk

4.10 – 4.30 pm **Break**

4.30 – 6.15 pm

Session 6: Determinants of response to immunotherapy

Arlene Sharpe - Harvard Medical School (USA)

Overcoming microbiome-related resistance to PD-1/PD-L1 cancer immunotherapy

Paola Nisticò – IFO Regina Elena National Cancer Institute (Italy)

Ira Mellman – Genentech (USA)

2 Proffered talks

Day 4 – Saturday, September 23, 2023

8.15 – 8.55 am

AACR Keynote Lecture

Antoni Ribas – University of California Los Angeles (USA)

9.00 – 10.15 am

Round table 5: What we can learn from hematologic malignancies


Chiara Bonini – IRCCS Ospedale San Raffaele (Italy)

Max Topp - Universitätsklinikum Würzburg (Germany)

Matteo Bellone - IRCCS Ospedale San Raffaele (Italy)

Impact of diet and microbiota on immunotherapy for plasma cell dyscrasias

General discussion



10.15 – 10.45 am **Break**

10.45 am– 12.15 pm **Session 7: *Bang on target: modulating the microbiota to improve cancer immunotherapy***

Florencia McAllister – MD Anderson Cancer Center (USA)

Laurence Zitvogel - Gustave Roussy Cancer Campus (France)
Microbiota-dependent emigration of enterotropic T cells to tumors

Kathy McCoy - University of Calgary (Canada)
Identifying microbes and metabolites that modulate cancer immunotherapy to translate discovery to treatment

1 Proffered talk

12.15 – 2.00 pm **Session 8: *Cellular therapies: arming immune cells***
Carl June – to be confirmed

Cassian Yee - University of Texas (USA)
T Cell Therapy meets ChatGPT: a chalk talk for 2023

Giampietro Dotti - University of North Carolina Lineberger Comprehensive Cancer Center

2 Proffered talks

2.00 pm **Closing remarks and meeting ends**